Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform December 9, 2024
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia September 30, 2024
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B June 4, 2024
